RxDoctor Payments Data

Nicholas Tarangelo, MD

Gastroenterology · Morristown, NJNPI 1073909925

Payments from drug & device makers

$5,363in general payments, 2019–2025

Across 327 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$844
  • QOL Medical, LLC$418
  • Aimmune Therapeutics, Inc.$345
  • Takeda Pharmaceuticals U.S.A., Inc.$272
  • Lilly USA, LLC$223
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,363 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$230,222
Medicare patients
706
Services billed
2,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase18$292,244
XifaxanRifaximin32$99,498
InflectraInfliximab-Dyyb13$97,134
RemicadeInfliximab12$72,862
IbsrelaTenapanor Hcl23$38,371
LinzessLinaclotide18$20,260
Mesalamine50$16,025
SutabSod Sulf/Pot Chloride/Mag Sulf45$7,272
Sucralfate36$5,131
Esomeprazole Magnesium30$4,989
Dexlansoprazole DrDexlansoprazole14$4,606
Pantoprazole Sodium225$4,064
Omeprazole160$2,578
Budesonide EcBudesonide11$2,459
Budesonide DrBudesonide12$1,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,662$312,50436 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$844$99,49832 claims
PfizerInflectra$180$97,13413 claims
Johnson & JohnsonRemicade$216$72,86212 claims
Ardelyx, Inc.Ibsrela$159$38,37123 claims
Braintree Laboratories, Inc.Sutab$81$7,27245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →